logo
Share SHARE
FONT-SIZE Plus   Neg

GSK Announces Data From Five Phase III Studies Of Albiglutide - Quick Facts

U.K.-based drug maker GlaxoSmithKline plc (GSK, GSK.L) announced data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes.

The company presented the data at the American Diabetes Association Meeting in Chicago from five long-term Phase III studies comparing albiglutide, an investigational glucagon-like peptide receptor agonist (GLP-1), to placebo and a range of active comparators.

The company said that the primary efficacy endpoint for these studies was the change from baseline in HbA1c compared to placebo and/or active comparators assessed after one or two years of treatment. Secondary endpoints included fasting plasma glucose or FPG and weight. These studies were specifically designed to assess durability of albiglutide effect on HbA1c and other continuous variables when used in various combination therapies, at different stages of the disease, and in various degrees of renal impairment.

According to the company Albiglutide achieved the primary efficacy endpoint in these five studies, although a hierarchical analysis of noninferiority to pioglitazone was not met in one study. The most commonly reported adverse reactions in these studies were gastrointestinal (GI) complaints, primarily nausea and diarrhoea, and injection site reactions.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent. Albiglutide is currently undergoing regulatory review for the treatment of type two diabetes in the US and European Union.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
British American Tobacco plc Tuesday said it has agreed to buy the remaining 57.8 percent of Reynolds American Inc. it does not already own in $49.4 billion cash and stock deal. The companies said the deal would create a stronger, truly global tobacco and Next Generation Products company. The British tobacco major currently owns 42.2 percent of Reynolds. Ringling Bros. and Barnum & Bailey Circus, called as the Greatest Show on Earth, is coming to and end after 146 years of live entertainment. The decision reflects higher operating costs, and bigger than expected decline in ticket sales, mainly after the transition of the elephants off the circus. An investigation by Samsung Electronics Co Ltd. has found out that battery caused the fire issues with the abandoned Galaxy Note 7 smartphones, Reuters reported Monday, citing people familiar with the matter. The South Korean conglomerate has concluded the investigation into the explosions that resulted in the massive recall of Galaxy Note 7.
comments powered by Disqus
Follow RTT